Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1a first-in-human study of VRG50635 in healthy volunteers
NL-OMON56052Phase 1Recruiting
- Sponsor
- Verge Genomics
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing VRG50635 with Placebo (2 arms). Started Sep 2022; status: recruiting.
02
Drugs
VRG50635
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NL-OMON56052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56052.